Hello and welcome to the details of India’s Serum Institute applies for full approval of Covishield vaccine and now with the details
BENGALURU, Dec 31 — Serum Institute Of India has applied to the country’s drug regulator and the health ministry for full approval of its Covid-19 vaccine Covishield, the company’s chief executive said on Friday.
Serum Institute, which produces AstraZeneca’s Covid-19 vaccine under the brand name Covishield, has supplied more than 1.25 billion doses of the shot in India.
The Indian government now has enough data to consider a full market authorisation, Serum Institute CEO Adar Poonawalla said on
.Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore @SerumInstIndia has applied to the @CDSCO_INDIA_INF (DCGI) and @MoHFW_INDIA for this permission.
— Adar Poonawalla (@adarpoonawalla) December 31, 2021
Serum Institute, which is also the world’s biggest vaccine maker, was granted approval for emergency use of Covishield in India at the beginning of the year.
The country’s inoculation drive so far has been dominated by Covishield and Bharat Biotech’s inactivated vaccine Covaxin.
Serum Institute has nearly quadrupled its monthly capacity of AstraZeneca’s shots to as many as 240 million doses and is prepared to export “large volumes” from January, Poonawalla told Reuters in October. — Reuters
These were the details of the news India’s Serum Institute applies for full approval of Covishield vaccine for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.